WHO WE ARE
A breakthrough alliance
T2EVOLVE works to accelerate development and increase access to immunotherapy with immune cells that harbor a genetically engineered T-cell receptor (TCR) or synthetic chimeric antigen receptor (CAR).
T2EVOLVE explained in 60 seconds
The T2EVOLVE Consortium is made up of 27 European partners from 9 different countries in 8 work packages. See how it works here.
Lymphodepletion: New article emphasises its essential but undervalued part of the CAR T-cell therapy cycle
Latest outcomes from T2EVOLVE
CAR T-cell therapy
Engineered T-cell therapy is a revolutionary cancer treatment where a patient’s immune cells are reprogrammed to seek and destroy cancer cells. This transformative treatment has the potential to cure cancer with a single shot. This therapy is approved and available in the EU for the treatment of leukemia and has the potential to become a blockbuster therapy for other types of cancer, as well as infectious diseases and autoimmune diseases in the future.
For additional information on CAR T-cell technology please contact UKW.
Director CAR-T Research Program, Cellular Immunotherapy for Malignant Diseases Max Eder Research Group‚ CAR T-cell engineering, Universitätsklinikum Würzburg, Germany
Translational Strategy Leader, Cell Therapies, Takeda Pharmaceuticals, and EFPIA project leader for T2EVOLVE IMI Consortium,
Cambridge, Massachusetts, USA
This project received funding from the innovative Medicines initiative 2 Joint Undertaking (JU) under grant agreement No 945393. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programe and EFPIA. More information can be found at: https://www.imi.europa.eu/